Brainsway (NASDAQ:BWAY - Get Free Report) will likely be issuing its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect the company to announce earnings of $0.05 per share and revenue of $14.6330 million for the quarter. Parties may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 8:30 AM ET.
Brainsway (NASDAQ:BWAY - Get Free Report) last issued its quarterly earnings results on Wednesday, March 11th. The company reported $0.14 earnings per share for the quarter, beating analysts' consensus estimates of $0.11 by $0.03. Brainsway had a net margin of 14.62% and a return on equity of 11.10%. The firm had revenue of $14.55 million during the quarter, compared to the consensus estimate of $14.02 million. On average, analysts expect Brainsway to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Brainsway Price Performance
Shares of Brainsway stock opened at $16.42 on Wednesday. Brainsway has a fifty-two week low of $4.30 and a fifty-two week high of $16.95. The firm has a fifty day moving average price of $14.09 and a two-hundred day moving average price of $11.20. The company has a market cap of $657.29 million, a PE ratio of 65.68 and a beta of 1.23.
Hedge Funds Weigh In On Brainsway
A number of hedge funds have recently made changes to their positions in the business. ARK Investment Management LLC acquired a new position in shares of Brainsway in the 4th quarter valued at $2,422,000. Two Sigma Investments LP raised its stake in shares of Brainsway by 25.2% in the 3rd quarter. Two Sigma Investments LP now owns 102,902 shares of the company's stock valued at $1,551,000 after buying an additional 20,706 shares in the last quarter. UBS Group AG raised its stake in shares of Brainsway by 2,028.6% in the 3rd quarter. UBS Group AG now owns 63,878 shares of the company's stock valued at $963,000 after buying an additional 60,877 shares in the last quarter. Millennium Management LLC raised its stake in shares of Brainsway by 69.6% in the 3rd quarter. Millennium Management LLC now owns 39,841 shares of the company's stock valued at $600,000 after buying an additional 16,354 shares in the last quarter. Finally, NewEdge Advisors LLC raised its stake in shares of Brainsway by 7.4% in the 3rd quarter. NewEdge Advisors LLC now owns 28,629 shares of the company's stock valued at $431,000 after buying an additional 1,964 shares in the last quarter. Institutional investors and hedge funds own 30.11% of the company's stock.
Wall Street Analyst Weigh In
BWAY has been the subject of a number of research reports. HC Wainwright reduced their price target on shares of Brainsway from $30.00 to $15.00 and set a "buy" rating for the company in a report on Thursday, March 12th. Weiss Ratings raised shares of Brainsway from a "hold (c)" rating to a "buy (b-)" rating in a report on Friday, April 24th. Zacks Research raised shares of Brainsway from a "hold" rating to a "strong-buy" rating in a report on Tuesday, March 24th. Northland Securities set a $15.00 price target on shares of Brainsway in a report on Thursday, January 22nd. Finally, Wall Street Zen raised shares of Brainsway from a "hold" rating to a "buy" rating in a report on Saturday, March 7th. One equities research analyst has rated the stock with a Strong Buy rating and three have assigned a Buy rating to the stock. Based on data from MarketBeat.com, Brainsway presently has a consensus rating of "Buy" and an average price target of $15.00.
Check Out Our Latest Stock Analysis on BWAY
About Brainsway
(
Get Free Report)
Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway's technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.
The company's flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Brainsway, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Brainsway wasn't on the list.
While Brainsway currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
SpaceX has quietly filed to go public later this year. Ahead of what's expected to be the largest IPO of all time, there are seven space stocks that you can buy today that are positioned to benefit from accelerating space commercialization in 2026.
These seven companies are shaping the next phase of the space economy—from launch leaders and satellite networks to data, defense, and in-space infrastructure.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
